Type 2 Diabetes Mellitus (T2DM) is a chronic and progressive condition characterised by worsening glucose control over time. This process is driven by deterioration of the cells in the body that make insulin, the pancreatic beta cells. Current therapies for early type 2 diabetes can improve glucose control but they do not protect the pancreatic beta cells from deterioration. PREVAIL is a government funded clinical trial for people with early T2DM. Our aim is to investigate therapies to protect the pancreatic beta cells and slow the progression of diabetes. We are currently inviting participants to join our study.
Mount Sinai Hospital is researching how to protect the cells in the body that produce insulin in order to slow the progression of diabetes and ideally reverse it. We are inviting participants to join our study.
Have had diabetes for 0-7 years, and take 0-2 oral medications for diabetes
This study has been approved by Mount Sinai's Research Ethics Board (MSH REB# #14-0128-A)
Health and Wellness
3 hour(s) per session
Do this one out of kindness
parking and/or local public transportation covered, and study supplies provided
60 Murray Street Toronto, Ontario, Canada, M5T 3L9